Pacira Pharma (PCRX) Reports Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia

Go back to Pacira Pharma (PCRX) Reports Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia
PACIRA (NASDAQ: PCRX) Delayed: 25.91 -0.44 (1.67%)
Previous Close $26.35    52 Week High $80.25 
Open $25.98    52 Week Low $30.25 
Day High $26.41    P/E N/A 
Day Low $25.68    EPS $-2.08 
Volume 116,383